Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
5.05
-0.01 (-0.20%)
Dec 5, 2025, 4:00 PM EST - Market closed
Taysha Gene Therapies Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Cash & Equivalents | 297.34 | 139.04 | 143.94 | 87.88 | 149.1 | 251.25 | Upgrade
|
| Cash & Short-Term Investments | 297.34 | 139.04 | 143.94 | 87.88 | 149.1 | 251.25 | Upgrade
|
| Cash Growth | 88.56% | -3.41% | 63.79% | -41.06% | -40.66% | - | Upgrade
|
| Prepaid Expenses | 0.81 | 1.36 | 1.09 | 2.51 | 3.87 | 3.83 | Upgrade
|
| Restricted Cash | 0.45 | 0.45 | 0.45 | - | - | - | Upgrade
|
| Other Current Assets | 1.35 | 1.28 | 4.39 | 6.03 | 6.63 | 2.79 | Upgrade
|
| Total Current Assets | 299.95 | 142.13 | 149.87 | 96.42 | 159.6 | 257.88 | Upgrade
|
| Property, Plant & Equipment | 14.27 | 15.87 | 20.41 | 25.91 | 50.61 | 0.29 | Upgrade
|
| Other Long-Term Assets | 2.34 | 2.37 | 2.46 | 3.95 | 3.74 | 0.72 | Upgrade
|
| Total Assets | 316.55 | 160.36 | 172.73 | 126.28 | 213.96 | 258.88 | Upgrade
|
| Accounts Payable | 5.44 | 3.59 | 6.37 | 10.95 | 21.76 | 1.99 | Upgrade
|
| Accrued Expenses | 14.39 | 9.59 | 9.46 | 14.04 | 25.85 | 4.87 | Upgrade
|
| Current Portion of Leases | 1.67 | 1.88 | 1.65 | 1.52 | - | - | Upgrade
|
| Current Unearned Revenue | 5.49 | 9.77 | 18.11 | 33.56 | - | - | Upgrade
|
| Other Current Liabilities | 1.65 | 1.4 | 1.18 | 2.73 | 4.14 | 0.26 | Upgrade
|
| Total Current Liabilities | 28.63 | 26.23 | 36.76 | 62.79 | 51.75 | 7.13 | Upgrade
|
| Long-Term Debt | 50.85 | 43.94 | 40.51 | 37.97 | 37.19 | - | Upgrade
|
| Long-Term Leases | 16.56 | 17.74 | 18.95 | 20.44 | 25.9 | - | Upgrade
|
| Other Long-Term Liabilities | 1.52 | 0.93 | 1.58 | 4.13 | 3.74 | 0.45 | Upgrade
|
| Total Liabilities | 97.57 | 88.84 | 97.79 | 125.33 | 118.57 | 7.58 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | - | - | Upgrade
|
| Additional Paid-In Capital | 903.58 | 677.86 | 587.94 | 402.39 | 331.03 | 312.43 | Upgrade
|
| Retained Earnings | -683.45 | -602.31 | -513.01 | -401.44 | -235.65 | -61.13 | Upgrade
|
| Comprehensive Income & Other | -1.14 | -4.03 | - | - | - | - | Upgrade
|
| Shareholders' Equity | 218.99 | 71.53 | 74.94 | 0.95 | 95.38 | 251.3 | Upgrade
|
| Total Liabilities & Equity | 316.55 | 160.36 | 172.73 | 126.28 | 213.96 | 258.88 | Upgrade
|
| Total Debt | 69.08 | 63.56 | 61.11 | 59.93 | 63.09 | - | Upgrade
|
| Net Cash (Debt) | 228.26 | 75.48 | 82.83 | 27.95 | 86.01 | 251.25 | Upgrade
|
| Net Cash Growth | 141.11% | -8.88% | 196.34% | -67.50% | -65.77% | - | Upgrade
|
| Net Cash Per Share | 0.77 | 0.30 | 0.71 | 0.64 | 2.28 | 14.22 | Upgrade
|
| Filing Date Shares Outstanding | 273.92 | 205 | 187.02 | 63.47 | 38.47 | 37.76 | Upgrade
|
| Total Common Shares Outstanding | 273.92 | 204.94 | 186.96 | 63.21 | 38.47 | 37.76 | Upgrade
|
| Working Capital | 271.32 | 115.9 | 113.11 | 33.63 | 107.86 | 250.75 | Upgrade
|
| Book Value Per Share | 0.80 | 0.35 | 0.40 | 0.02 | 2.48 | 6.65 | Upgrade
|
| Tangible Book Value | 218.99 | 71.53 | 74.94 | 0.95 | 95.38 | 251.3 | Upgrade
|
| Tangible Book Value Per Share | 0.80 | 0.35 | 0.40 | 0.02 | 2.48 | 6.65 | Upgrade
|
| Machinery | 4.75 | 4.7 | 4.87 | 4.88 | 3.04 | 0.1 | Upgrade
|
| Construction In Progress | 4.32 | 4.25 | 6.82 | 9.63 | 46 | 0.2 | Upgrade
|
| Leasehold Improvements | 2.12 | 2.12 | 2.12 | 2.09 | 2.07 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.